We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
-1.57%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$6.49B
AUM Growth
-$396M
(-5.7%)
Cap. Flow
-$220M
Cap. Flow
% of AUM
-3.39%
Top 10 Holdings %
Top 10 Hldgs %
43.16%
Holding
163
New
23
Increased
16
Reduced
43
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LIAN
LianBio American Depositary Shares
LIAN
|
+$643M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$97.4M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$50.7M |
| 4 |
ISO
IsoPlexis Corporation Common Stock
ISO
|
+$45.4M |
| 5 |
Zentalis Pharmaceuticals
ZNTL
|
+$33.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$79.2M |
| 2 |
NVTA
Invitae Corporation
NVTA
|
+$50.6M |
| 3 |
Beam Therapeutics
BEAM
|
+$46.8M |
| 4 |
DBVT
DBV Technologies
DBVT
|
+$37.7M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$30M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.98% |
| 2 | Miscellaneous | 13.04% |
| 3 | Financials | 0.8% |
| 4 | Industrials | 0.09% |
| 5 | Consumer Staples | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CYPH
51
Cypherpunk Technologies Inc
CYPH
$239M
| $27.5M | 0.42% |
847,650
| – | – |
|
52
Establishment Labs
ESTA
$2.13B
| $27.4M | 0.42% |
405,541
-100,000
| -20% | -$6.99M |
|
53
Cogent Biosciences
COGT
$5.68B
| $27.4M | 0.42% |
3,188,750
| – | – |
|
|
CMAX
54
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $27.3M | 0.42% |
118,318
+5,485
| +5% | +$1.3M |
|
55
MacroGenics
MGNX
$257M
| $26.7M | 0.41% |
1,665,243
-482,817
| -22% | -$9.09M |
|
56
Veru
VERU
$39.9M
| $26.2M | 0.4% |
445,134
| – | – |
|
57
Nuvation Bio
NUVB
$2.04B
| $24.8M | 0.38% |
2,920,823
-120,181
| -4% | -$1.1M |
|
58
Pulmonx
LUNG
$82M
| $24.4M | 0.38% |
+762,304
| New | +$27.8M |
|
|
NVTA
59
DELISTED
Invitae Corporation
NVTA
| $24.2M | 0.37% |
1,584,585
-2,339,156
| -60% | -$50.6M |
|
60
Solid Biosciences
SLDB
$897M
| $23.5M | 0.36% |
894,170
| – | – |
|
61
Pyxis Oncology
PYXS
$278M
| $21.3M | 0.33% |
+1,944,114
| New | +$22.3M |
|
|
HLTH
62
DELISTED
Cue Health Inc. Common Stock
HLTH
| $21.2M | 0.33% |
1,580,607
| – | – |
|
63
United Therapeutics
UTHR
$21.5B
| $20.3M | 0.31% |
94,064
-47,636
| -34% | -$9.35M |
|
|
VRNA
64
DELISTED
Verona Pharma
VRNA
| $19.3M | 0.3% |
2,867,510
-21,379
| -0.7% | -$109K |
|
|
SNCE
65
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $18.7M | 0.29% |
75,000
+60,000
| +400% | +$13.3M |
|
|
ATNX
66
DELISTED
Athenex, Inc. Common Stock
ATNX
| $18.4M | 0.28% |
676,623
| – | – |
|
67
Treace Medical Concepts
TMCI
$298M
| $18.3M | 0.28% |
980,186
-255,700
| -21% | -$5.28M |
|
68
Health Catalyst
HCAT
$129M
| $18M | 0.28% |
454,004
-135,000
| -23% | -$6.15M |
|
|
DICE
69
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $17.8M | 0.28% |
+704,885
| New | +$20.7M |
|
|
SLGC
70
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $17.5M | 0.27% |
1,500,000
-550,000
| -27% | -$6.59M |
|
71
ADMA Biologics
ADMA
$1.93B
| $16.8M | 0.26% |
11,933,387
-1,328,988
| -10% | -$1.75M |
|
|
NUVL
72
DELISTED
Nuvalent
NUVL
| $14.3M | 0.22% |
750,000
| – | – |
|
|
LYRA
73
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $14.1M | 0.22% |
64,451
| – | – |
|
74
Viatris
VTRS
$19.1B
| $13.6M | 0.21% |
1,004,419
| – | – |
|
|
FLNA
75
PUT
Filana Therapeutics
FLNA
$33.6M
| $13.1M | 0.2% |
300,000
+200,000
| +200% | +$10.5M |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q4 2021 Portfolio in Review
As of Q4 2021, Perceptive Advisors held 163 positions worth $6.49B, down 5.7% from $6.88B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Perceptive Advisors withdrew a net $220M in Q4 2021, closing 16 positions and reducing 43 holdings. Its most notable exit was Atea Pharmaceuticals, an estimated $79.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in LianBio American Depositary Shares worth $347M.
- Perceptive Advisors's largest Q4 2021 buy was LianBio American Depositary Shares: 56,319,960 shares worth $347M.
- Perceptive Advisors added most to Apellis Pharmaceuticals in Q4 2021, an estimated $32.9M increase.
- Perceptive Advisors's biggest Q4 2021 reduction was Invitae Corporation, cutting an estimated $50.6M.
- Perceptive Advisors fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $79.2M.
- Perceptive Advisors's ten largest holdings make up 43% of its $6.49B portfolio in Q4 2021.
- Perceptive Advisors opened 23 new positions and closed 16 in Q4 2021.
- Perceptive Advisors's portfolio value fell 5.7% quarter-over-quarter to $6.49B.
Based on Perceptive Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.